Viatris Launches Inpefa in UAE: A New Milestone for Heart Failure Treatment Access
Market Chameleon (Tue, 20-Jan 4:27 AM ET)
PRNewswire (Tue, 20-Jan 6:59 AM ET)
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
PRNewswire (Thu, 8-Jan 9:05 AM ET)
Globe Newswire (Tue, 6-Jan 9:00 AM ET)
Viatris Provides Pipeline Update on Four Regulatory Milestones
PRNewswire (Thu, 18-Dec 6:59 AM ET)
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference
PRNewswire (Wed, 17-Dec 6:59 AM ET)
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
PRNewswire (Sat, 6-Dec 9:00 AM ET)
Viatris to Participate in Upcoming Investor Conferences
PRNewswire (Mon, 24-Nov 8:00 AM ET)
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Globe Newswire (Thu, 20-Nov 7:30 AM ET)
Viatris Recognized as One of the Fortune World's Best Workplaces in 2025
PRNewswire (Thu, 13-Nov 8:00 AM ET)
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Viatris trades on the NASDAQ stock market under the symbol VTRS.
As of January 22, 2026, VTRS stock price climbed to $13.24 with 5,336,096 million shares trading.
VTRS has a beta of 1.05, meaning it tends to be more sensitive to market movements. VTRS has a correlation of 0.24 to the broad based SPY ETF.
VTRS has a market cap of $15.25 billion. This is considered a Large Cap stock.
Last quarter Viatris reported $4 billion in Revenue and $.67 earnings per share. This beat revenue expectation by $139 million and exceeded earnings estimates by $.05.
In the last 3 years, VTRS traded as high as $13.62 and as low as $6.85.
The top ETF exchange traded funds that VTRS belongs to (by Net Assets): VTI, VOO, VB, VBR, IVV.
VTRS has outperformed the market in the last year with a price return of +21.1% while the SPY ETF gained +15.5%. VTRS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +28.6% and +6.3%, respectively, while the SPY returned +2.9% and -0.1%, respectively.
VTRS support price is $12.81 and resistance is $13.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VTRS shares will trade within this expected range on the day.